<DOC>
	<DOCNO>NCT00437112</DOCNO>
	<brief_summary>A study compare Human Inhalation Powder ( also know AIR® Inhaled Insulin ) ( AIR® register trademark Alkermes , Inc. ) insulin glargine injection patient Type 2 diabetes currently take oral medication previously take insulin . Change HbA1c level review determine superiority inferiority AIR Inhaled Insulin regimen .</brief_summary>
	<brief_title>Evaluate Efficacy Safety Insulin Compared Glargine Patients With Type 2 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Insulin Glargine</mesh_term>
	<criteria>Type 2 Diabetes Mellitus Insulin naive One oral antihyperglycemic medication HbA1c great equal 8.0 % less equal 10.5 % Nonsmoker Taking TZD dose great indicate Have take insulin within 6 month entry study Have 2 episode sever hypoglycemia 6 month prior study entry Have 1 hospitalization emergency room visit due poor diabetic control 6 month prior study entry Have pneumonia 3 month prior study entry Systemic glucocorticoid therapy Clinical sign symptoms liver disease , acute chronic hepatitis History renal transplantation Have active untreated malignancy Have current diagnosis past history clinically relevant pulmonary disease Taking take exenatide 6 week prior study entry</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2008</verification_date>
</DOC>